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Abstract
Global transcriptome analysis of whole blood RNA using microarrays has been proven to be challenging due to the high
abundance of globin transcripts that constitute 70% of whole blood mRNA. This is a particular problem in patients with
sickle cell disease, secondary to the high abundance of globin-expressing nucleated red blood cells and reticulocytes in the
circulation. In order to accurately measure the steady state blood transcriptome in sickle cell patients we evaluated the
efficacy of reducing globin transcripts in PAXgene stabilized RNA for genome-wide transcriptome analyses using
microarrays. We demonstrate here by both microarrays and Q-PCR that the globin mRNA depletion method resulted in 55–
65 fold reduction in globin transcripts in whole blood collected from healthy volunteers and sickle cell disease patients. This
led to an improvement in microarray data quality by reducing data variability, with increased detection rate of expressed
genes and improved overlap with the expression signatures of isolated peripheral blood mononuclear (PBMC) preparations.
Analysis of differences between the whole blood transcriptome and PBMC transcriptome revealed important erythrocyte
genes that participate in sickle cell pathogenesis and compensation. The combination of globin mRNA reduction after
whole-blood RNA stabilization represents a robust clinical research methodology for the discovery of biomarkers for
hematologic diseases.
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Introduction
Discovery of transcriptional biomarkers represents a promising
strategy in the field of translational medicine for early disease
detection, the development of personalized therapy for complex
diseases, and for the definition of disease specific signaling
pathways [1,2]. In this regard, microarray based transcriptome
analysis appears to be a frontier technology for the identification of
potential biomarkers by application to biological materials most
relevant to the phenotypes under investigation. These include
biopsy materials from fine needle aspirates (FNA), cell sub-
populations, or enriched isolates from laser capture microdissec-
tion (LCM). Although transcriptional profiles in such target disease
tissues/cells are ideal for such analyses, the complexity of
procuring such tissue biopsies/cells and the low amount of RNA
from these specimens for standard microarray assays has made
whole blood, a practical and an attractive surrogate tissue in
clinical research [3,4,5,6,7]. The ready availability of blood, non/
minimally invasive method of specimen collection and the critical
role of blood cells in immune response out-measure the advantages
of blood to tissue biopsies/cells in measuring disease state and drug
response. Using a global transcriptional analysis of PBMC cells
from patients with sickle cell disease we identified important
disease modifying pathways, including upregulation of catalytic
antioxidant (Peroxiredoxin, Glutathione peroxidase, glutathione S
transferase, Thioredoxin) and anti-proliferative cell cycle regula-
tors (Heme oxygenase 1, Biliverdin Reductase and P21 [1].
Traditionally whole blood samples for gene expression were
collected in CPT tubes (Becton Dickinson) with an anticoagulant.
However, RNA expression profiles have been observed to change
over time in such fractionated samples [4,8] thereby implying the
need for stabilization of RNA between sample collection and
isolation to maintain the expression profile of blood cells. Though
this was achieved by the isolation of peripheral blood mononuclear
cells immediately after specimen collection, the labor intensive
techniques involved in this process and the need for technical
experts in the field at the time of sample collection hinder its
applicability in large scale multi center clinical trials. Attempts to
overcome these hurdles led to the development of new approaches
that would ease the sample collection and RNA stabilization [9].
In this respect, the PAXgene (PAX) blood RNA system has been
widely employed in gene expression studies of peripheral blood.
Although, this system employs an easy way to collect, store,
transport and stabilize RNA from whole blood, many studies have
demonstrated that RNA prepared from the PAXgene blood tubes
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the transcript detection sensitivity using microarrays [6]. The
observed anomalies have largely been attributed to the presence of
predominant amounts of globin transcripts that constitute ,70%
of mRNA in whole blood samples [7]. We found that this
represents a major problem for the study of hemolytic anemias,
such as sickle cell disease, owing to the high abundance of globin
transcripts in nucleated erythrocytes and reticulocytes. Addressing
these limitations, we undertook the current study of evaluating
methods that combine stabilization of RNA and reduction of
globin transcripts in whole blood to determine the suitability of the
globin reduced RNA for microarray based transcriptome studies
in sickle cell disease. We demonstrate herein that efficient removal
of globin transcripts in PAXgene stabilized whole blood
significantly improves the detection sensitivity of transcripts on
microarrays and enhances the identification of genes that are
significantly modulated during the sickle cell disease process. We
also report here our observations on the similarities and
dissimilarities of the expressed transcripts in the PBMCs and
globin enriched and globin depleted whole blood. From a
biological perspective, the globin depleted PAX gene versus the
PBMC difference expression profile provides a window into real
time erythrocyte expression profiles in sickle cell disease.
Methods
Patients and Control Subjects
The study was approved by the National Heart Lung and Blood
Institute’s institutional review board and written informed
consents were obtained from study participants. Patients selected
for this study included 10 patients with sickle cell disease of mean
age 41.6610.1 and the control self-identified 10 African American
subjects of mean age 42.268.9. The patient’s samples were
collected in steady state condition and none were on anti-platelet
medication. Expression profiles (Control N=5; SCD N=5) were
compared to differential gene expression data generated in a prior
study of 27 patients and 13 controls [1].
Peripheral blood mononuclear cell isolation and RNA
isolation
Peripheral blood from sickle cell patients, and healthy African-
American volunteers, was collected into Vacutainer cell prepara-
tion tube (CPT) with sodium citrate and Ficoll (Becton Dickinson,
Franklin Lakes, NJ). Purified peripheral blood mononuclear cell
(PBMC) suspensions were resuspended in buffer RLT (700–
1000 mL per 10
7 cells) and passed through Qiashredder columns
(Qiagen, Valencia, CA) then stored at –70u C. Total RNA was
extracted from peripheral blood mononuclear cells using RNeasy
Mini Kit (Qiagen).
Isolation of RNA from whole blood specimens
Blood Specimen (2.5 ml) collected in PAXgene
TM tubes from
each subject was incubated at room temperature for 4 h for RNA
stabilization and then stored at 2 80 uC. RNA was extracted from
whole blood using the PAXgene
TM Blood RNA System Kit
following the manufacturer’s guidelines. Briefly, samples were
removed from 280uC and incubated at room temperature for
2 hours to ensure complete lysis. Following lysis, the tubes were
centrifuged for 10 min at 5,0006g the supernatant was discarded
and 500 mL of RNase-free water added to the pellet. The tube was
vortexed thoroughly to re-suspend the pellet, centrifuged for
10 min at 50006g and the entire supernatant was discarded. The
pellet was re-suspended in 360 mL of buffer BR1 by vortexing and
further purification of RNA was done following the manufactur-
er’s protocol with on-column DNase digestion.
Quality of the purified RNA from was verified on an AgilentH
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA); RNA
concentrations were determined using a NanoDropH ND-1000
spectrophotometer (NanoDrop Technologies, Wilmington, DE).
Depletion of Globin Transcripts
Globin mRNA was depleted from a portion of each total RNA
sample isolated from PAXgene tubes using the GLOBINclear
TM-
Human kit (Ambion, Austin, TX). In brief 2 mg of total RNA from
human whole blood was mixed with a biotinylated Capture Oligo
Mix in hybridization buffer. The mixture was incubated for 15
minutes to allow the biotinylated oligonucleotides to hybridize
with the globin mRNA species. Streptavidin magnetic Beads were
then added, to capture the globin mRNA and the magnetic beads
were then pulled to the side of the tube with a magnet and the
RNA, depleted of the globin mRNA, was transferred to a fresh
tube. The RNA was further purified using a rapid magnetic bead-
based purification method as suggested by the manufacturer.
Preparation of biotinylated cRNA targets for gene chip
hybridizations
The cRNA labeling and hybridizations were performed
according to protocols from Affymetrix Inc. (Santa Clara, CA).
Briefly, 1 mg of total RNA from PBMC, whole blood (PAX) and
Globin depleted (PAX-GR) samples was converted to double-
stranded cDNA with a T7-(dT) 24 primer. The cDNA was in vitro
transcribed to biotinylated complementary RNA (cRNA) by
incorporating biotin-CTP and biotin-UTP using affymetrix IVT
labeling kit. Twenty mg of biotin-labeled RNA was fragmented to
,200 bp size by incubating in fragmentation buffer containing
200 mM Tris-acetate pH 8.2, 500 mM potassium acetate and
500 mM magnesium acetate for 35 minutes at 94uC prior to
hybridization. Fragmented RNA was assessed for relative length
on Agilent 2100 bioanalyzer and hybridized to Affymetrix HG-
U133 plus 2.0 chips for 16 hours, washed, stained on an
Affymetrix fluidics station and scanned using Affymetrix genechip
scanner.
Microarray Data Processing and Analysis
Affymetrix GCOS version 1.4 was used to calculate the signal
intensity and the percent present calls on the hybridized Affymetrix
chip. The signal intensity values obtained for probe sets in the
microarrays were transformed using an adaptive variance-stabiliz-
ing, quantile-normalizing transformation termed ‘‘S10’’ (described
in Munson, P.J., GeneLogic Workshop of Low Level Analysis of
Affymetrix GeneChip Data, 2001, http://stat-www.berkeley.edu/
users/terry/zarray/Affy/GL_Workshop/genelogic2001.html, soft-
ware available at http://abs.cit.nih.gov/geneexpression.html.).
This S10 transformation serves to make the variances uniform up
and down the measurement scale, while at the same time allowing
direct comparisons of transformed intensities between chips, and
renders the data in a scale nearly matching the base 10 logarithm in
the central range of measurement. Transformed data from all the
chips were subjected to a principal component analysis (PCA) to
allow for detection of outliers. Student t-test between sickle and
control was performed for PBMC, PAX and PAX globin-reduced
respectively and the p-value for differences between two groups was
calculated for each of the 54,675 Probe Sets. To address the
multiple comparisons problem, false discovery rate (FDR) was
calculatedforeachprobeset.FDRfilterswere appliedinadditionto
fold change (FC) cutoff. Two-way hierarchical clustering was used
Whole Blood Gene Expression
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pattern. The hierarchical cluster is run from the JMP statistical
software package (www.jmp.com, Cary, NC) using the ward
method.
To compare this data with previously published data which was
generated on HG-U95 array, array comparison data for best match
from HG-U95 to HG-U133 plus 2.0 arrays downloaded from
Affymetrix website were used to map probe sets between the two
arrays. Gene ontology analysis was done using DAVID Bioinfor-
matics Resources 2007 online (http://david.abcc.ncifcrf.gov/)
All the microarray data reported in this manuscript is described
in accordance with the MIAME guidelines. The data has also been
submitted to GEO and the submission # is GSE 16728.
Real Time Q-PCR analysis
First-strand cDNA was synthesized using 500 ng of RNA and
random primers in a 20 ml reverse transcriptase reaction mixture
using Invitrogen’s Superscript cDNA synthesis kit (Invitrogen,
Carlsbad,CA)followingthe manufacturer’sdirections.Quantitative
real-time PCR assays were carried out with the use of gene-specific
double fluorescently labeled probes in a 7900 Sequence Detector
(PE Applied Biosystems, Norwalk, CT). Probes and primers were
obtained from Applied Biosystems. In brief, PCR amplification was
performed in a 384 well plate with a 20-ml reaction mixture
containing 300 nm of each primer, 200 nm probe, 200 nm dNTP
in 1x real time PCR buffer and passive reference (ROX)
fluorochrome. The thermal cycling conditions were 2 min at 50u
C and 10 min at 95u C, followed by 40 cycles of 15 sec denaturation
at 95u C and 1 minannealingandextension at60u C. Samples were
analyzed in duplicate and the CT values obtained were normalized
to the housekeeping gene b actin. The comparative CT (DDCT)
method which compares the differences in CT values between
groups to achieve the relative fold change in gene expression.
Results
Quality of total RNA and biotinylated cRNA from PBMC,
PAX and PAX-GR
Examination of the isolated total RNA from PBMC, PAX,
PAX-GR on a lab on a chip system found them to be of high
quality with intact 18s and 28s ribosomal RNA with RIN numbers
greater than 9.0 as shown in Figure 1A. There was about 20–25%
loss of RNA during globin depletion process. 1 mg of total RNA
from PBMC, PAX AND PAX-GR was processed for the synthesis
of biotinylated cRNA for gene chip hybridizations. The cRNA
yield from these samples were in the range of 2564.1 with an
acceptable 260/280 ratio of 1.9–2.1. On analysis using the
bioanalyzer, a pronounced peak corresponding to ,700 nucleo-
tides representing globin cRNA was found to be present only in
PAX RNA samples. The PBMC and PAX-GR samples showed
identical smear pattern of cRNA products as shown in Figure 1B
suggesting the depletion of substantial amounts of globins in the
PAX-GR samples.
Expression of Globin transcripts by RT-PCR and
microarrays
To confirm the effectiveness of globin mRNA reduction, RNA
samples from both PAX and PAX-GR samples were analyzed by
Figure 1. A. Quality of total RNA from PBMC, PAX and PAX-GR. The intact 18 and 28s ribosomal bands are shown in the electophoregram
determined in agilent bioanalyzer. B. Quality of biotinylated cRNA from PBMC, PAX and PAX-GR. A predominant 700 bp peak represents the globin
cRNA in the PAX samples. cRNA from PBMC and PAX-GR show a similar pattern of a smear of transcripts. 1. Red line - PAX. 2. Blue line - PAX- GR. 3.
Green line - PBMC.
doi:10.1371/journal.pone.0006484.g001
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and the normalized CT values were calculated using 18s as the
house keeping gene. There was significant depletion of both the
alpha and beta globins in PAX-GR samples as represented by the
increase in delta CT values (normalized to 18S RNA) for both beta
and alpha as a sequel to globin reduction as depicted in Figure 2A.
Gamma globins did not show a significant difference between the
PAX and PAX-GR samples. Examination of the S10 transformed
signal intensity for the alpha and beta globins in the PAX and
PAX-GR samples showed a similar pattern in the globin
expression level with a signal intensity difference of .0.3 (or
approximately log10 2 fold representing about 3 fold on the S10
transform scale) between the PAX and PAX-GR for both the
alpha and beta globin genes. (Figures 2B & C).
Microarray analysis of expressed transcripts in PBMC, PAX
and PAX-GR
Upon hybridization of the biotinylated cRNA to HG U133 plus
2.0 gene chips, increased sensitivity in the detection of expressed
transcripts was observed in PAX-GR samples as evaluated by the
number of genes called above background (Present Calls), scaling
factor, and signal intensity. Scale factor, an indirect measure of
signal, with lower values indicating higher array signal decreased
substantially from both control and SCD samples after globin
depletion from 28612.0 to 11.263.7. This thereby resulted in an
increase in average signal and greater sensitivity throughout the
distribution. Higher signal, especially for weakly expressed genes,
resulted in better estimates of present calls. The highest number of
transcripts was detected in the PBMC samples followed by PAX-
GR and PAX respectively. Figure 3 shows this increase in
detection sensitivity as evidenced by the increase in detectable
transcripts after globin reduction in both control and SCD
samples. Depletion of globins from both the control and SCD
patient’s samples increases the present call rate by 22–25% and
this increase in detection sensitivity was more pronounced with the
SCD samples.
In order to determine if globin reduction decreases intra sample
variability a scatter plot analysis of all array elements was
performed by comparing two control subjects on the 3 different
sample types. PBMC samples showed the highest correlation
(R
2=0.92) and lowest variability between the samples while the
PAX samples had an R
2 of only 0.71. However, upon globin
Figure 2. A. Expression of 18s, globin transcripts a, b by RT-PCR in PAX and PAX-GR from control and SCD samples. Ct values in the expression of
globins are given as mean6SD for each group. Red bar - PAX-Control; Green bar - PAX-GR Control; Yellow bar - PAX-SCD; Blue bar - PAX-GR-SCD. B.
Normalized signal intensities for b globin probe sets from microarrays for control and SCD samples. Values are given as mean6SD. Grey bar - PAX;
Black bar - PAX-GR. C. Normalized signal intensities for a globin probesets from microarrays for control and SCD samples. Values are given as
mean6SD. Grey bar - PAX; Black bar - PAX-GR.
doi:10.1371/journal.pone.0006484.g002
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2 value increased
to 0.89. Further analysis of the genes expressed genes in either
control and sickle cell disease samples using either the PAX and
PAX – GR preparation showed that the median Mean Square
Error (MSE) within group (SCD or control) to be 0.0063 for the
PAX samples and 0.0037 for PAX-GR samples. This clearly
demonstrates a substantial, greater than 40% reduction in the
error variance, using the Globin reduction technique.
A comparative analysis of expressed transcripts from the control
and patient sample sets demonstrated a strong overlap of genes
between the PAX-GR and PBMC with 11136 transcripts
overlapping with 12088 transcripts from PBMCs. PAX samples
on the other hand showed a lesser number (8954) overlapping with
the PBMCs as shown in Figure 4. Similarly in SCD samples the
overlap of transcripts between PBMC and PAX-GR was stronger
with 10403 probe sets overlapping with 12134 transcripts in
PBMCs than PAX with only 8208 probe sets overlapping with
PBMCs. Between PAX and PAX-GR, the overlap was 88.8% in
the control subjects and 94.4% in SCD patients suggesting that
globin depletion process does not significantly alter the expression
pattern of whole blood. Table 1 lists selected genes from this
category of unaltered genes. GO analysis of genes that are
common to both PAX and PAX-GR showed them to possess
nucleic acid binding activity (27%), cytoskeletal protein binding
(24.9%), transcription factor binding (17.9%) and enzyme activity
(16.9%) as shown in Figure 5. Interestingly, globin depletion
process unmasks 3,023 transcripts in the control samples and
5,644 transcripts from the SCD samples as evidenced by the ability
to detect them as present calls in PAX-GR samples. Table 2 lists
few selected genes that were unmasked by globin depletion process
as evidenced by the transformation of an absent call to a present
call along with few selected genes that remain unaltered. The
unmasked genes examined by gene ontology analysis appear to
function as binding proteins and enzymes involved in biological
processes such as transcription, intracellular transport and
biochemical signaling. The 100 genes representing hypothetical
proteins, cDNA clones, unknown transcripts and genes such as
hemochromatosis, hemoglobin epsilon 1 and transcribed locus
similar to alpha hemoglobin that were detectable only in PAX
samples were found to be masked or lost by globin reduction
process as indicated by the inability to detect them in PAX-GR
samples. BLAST analysis suggested that some of these transcripts
may have sequence similarities to globins.
Differential gene expression pattern in sickle cell disease
While comparing the globin depleted whole blood gene
expression profiles in patients with sickle cell disease and healthy
African American volunteer subjects using stringent statistical
filters of 20% false discovery rate and fold-change greater than 2,
we identified 909 significantly altered transcripts (Figure 6A).
These genes overlapped to a large extent with the differentially
regulated gene list from the PAX group of samples, and the fold
changes correlated strongly (R=0.96) as shown in Figure 6B
suggesting that the globin depletion process does not alter the
original whole blood gene expression profile of these subjects.
A closer examination of these differentially regulated genes after
filtering at 10% FDR and FC greater than 5 as shown in Figure 7
revealed significant up regulation of red cell specific genes such as
ankyrin, erythrocyte membrane protein band 3 and 4, hemoglo-
bins and glycophorin A in sickle cell disease. Other transcripts that
were identified to be differentially regulated in sickle cell disease
included BMP2 kinase, selenium binding protein, exportin,
spermine oxidase, peroxiredoxin 2, chemokines, interleukin
receptor and peptidyl arginine deaminase and these are known
to be key regulators in redox metabolism and inflammatory
processes as shown in Table 3. Few selected genes from the list of
differentially regulated genes with fold change .2, from the PAX-
GR group were validated by RT-PCR analysis and the results that
corroborate with the microarray data are shown in Table 4.
A comparative analysis of the differentially regulated genes from
the 3 different sample types from this study to our previous study
on PBMCs resulted in the mapping of 106 out of 112 probe sets
from previously published data to the current data. Further
analysis on the 106 probe sets showed a reasonably high
correlation to the PBMCs from the current study with a
correlation coefficient value of 0.51, followed by globin reduced
PAX with a correlation coefficient value of 0.41. A poor
correlation was observed with PAX samples with a correlation
coefficient value of only 0.21. It has to be borne in mind that these
studies were done in different batches using a totally different set of
Figure 3. Detection of expressed transcripts in PBMC, PAX and
PAX-GR in control (Grey bars) and SCD (Black bars) as
determined by the present calls for the samples (n=5)
analyzed by microarrays. Values are given as mean6SD for the
number of present transcripts in each of the groups in each sample
type.
doi:10.1371/journal.pone.0006484.g003
Figure 4. Venn diagram showing the relationship of present
calls between PBMC, PAX and PAX-GR in SCD samples.
doi:10.1371/journal.pone.0006484.g004
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Cell Cycle Regulation/Apoptosis
Probe set ID Gene Title Gene Symbol
201012_at annexin A1 ANXA1
208796_s_at cyclin G1 CCNG1
201095_at death-associated protein DAP
200046_at defender against cell death 1 DAD1
225153_at G elongation factor, mitochondrial 1 GFM1
201912_s_at G1 to S phase transition 1 GSPT1
225153_at G elongation factor, mitochondrial 1 GFM1
212508_at modulator of apoptosis 1 MOAP1
210907_s_at programmed cell death 10 PDCD10
Cell Signaling
204312_x_at cAMP responsive element binding protein 1 CREB1
219357_at GTP binding protein 1 GTPBP1
223640_at hematopoietic cell signal transducer HCST
1552263_at mitogen-activated protein kinase 1 MAPK1
1559052_s_at p21 activated protein kinase 2 PAK2
219628_at p53 target zinc finger protein WIG1
203497_at PPAR binding protein PPARBP
225649_s_at serine/threonine kinase 35 STK35
1552542_s_at T-cell activation GTPase activating protein TAGAP
Oxidoreductase/Antioxidant/Stress response
203773_x_at biliverdin reductase A BLVRA
205950_s_at carbonic anhydrase I CA1
219933_at glutaredoxin 2 GLRX2
200736_s_at glutathione peroxidase 1 GPX1
218120_s_at heme oxygenase (decycling) 2 HMOX2
200790_at ornithine decarboxylase 1 ODC1
200844_s_at peroxiredoxin 6 PRDX6
208864_s_at thioredoxin TXN
Chemokines/Interleukins/Coagulation
200800_s_at heat shock 70kDa protein 1A HSPA1A
201656_at integrin, alpha 6 ITGA6
204683_at intercellular adhesion molecule 2 ICAM2
202531_at interferon regulatory factor 1 IRF1
208200_at interleukin 1, alpha IL1A




200801_x_at actin, beta ACTB
204639_at adenosine deaminase ADA
201772_at antizyme inhibitor 1 AZIN1
200068_s_at calnexin CANX
200946_x_at glutamate dehydrogenase 1 GLUD1
200697_at hexokinase HK1
200650_s_at lactate dehydrogenase A LDHA
208980_s_at ubiquitin C UBC
doi:10.1371/journal.pone.0006484.t001
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Even considering these limitations, globin reduction improves the
correlation to the PBMCs from our previous study suggesting the
advantages of depleting globins in whole blood RNA for
microarray studies.
Discussion
Peripheral blood is an essential tissue type for biomedical
research because of its critical roles in immune response and
metabolism. The simplicity and ease of collection has also made
peripheral blood an attractive surrogate tissue for the discovery of
biomarkers of hematologic diseases and a wide range of
nonhematologic disorders. Thus, applying microarray technology
on peripheral blood may provide new insights of variations in
global gene expression specifically associated with states of normal
and disease and has the potential of applying the technology in
disease detection and diagnosis.
Although global gene expression technology had been successfully
applied on fractionated blood samples [10,11] such as PBMCs,
successful studies of gene expression profiles in whole-blood total
RNA have been limited due to heterogeneous cell types and potential
ex vivo changes from blood handling and processing. PBMCs with a
more uniform cell population, containing lymphocytes and mono-
cytes are the most transcriptionally active cells in blood [5] making it
an ideal study specimen. However, the extra fractionation procedure
for PBMCs requires a prolonged period before RNA stabilization,
and this has been shown to have significant ex vivo changes in gene
expression profiling [12,13]. In addition, in multicenter clinical trials,
isolation of PBMCs at the time of sample collection has been
considered to be a major shortcoming as skilled technicians are
n e e d e df o rp r o c e s s i n gt h es a m p l e sa tt h es i t ea n dt h i sc o u l da l s ol e a d
to operator induced variability in microarrys.
However, with the challenges unique to the whole blood
sample, including complex composition of heterogeneous cell
types and lower detection sensitivities and higher data variability,
it is difficult now to apply microarray technology on whole-blood
total RNA. It is widely believed that the abundant globin
transcripts in whole blood are the causative factors for the lowered
sensitivity and increased variability in microarray based gene
expression studies. The current study is an exploratory research
with the purpose of developing proper methods that would deplete
hemoglobin RNA from whole blood, for applying microarray
technology on globin depleted whole-blood total RNA. We chose
a globin abundant system namely sickle cell disease for this study
to evaluate the globin depletion process and also to discover novel
genes that are associated with sickle cell disease including cell types
such as nucleated red cells in addition to the conventional PBMCs.
Ambion’s globin clear method resulted in 55–65 fold depletion of
globin transcripts in whole blood and this ultimately led to a significant
Figure 5. Gene ontology classification for genes common to PAX and PAX – GR. Many genes have multiple gene ontology descriptions.
doi:10.1371/journal.pone.0006484.g005
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detection rate of expressed genes and this increase was more
pronounced in SCD. This increase in detection sensitivity appears
to be a reflection of higher signal intensity and lower signal to noise
ratio as evidenced by the transformation of an absent call to a present
call as shown in Table. 2. Interestingly, even after globin reduction the
PAX and PAX-GR samples by principal component analysis
clustered together rather than clustering with the PBMCs. More
Table 2. Representative Genes masked by globins and unmasked in PAX-GR.
Probe set ID Gene Title Symbol Detection
PAX-GR PAX
203271_s_at unc-119 homolog (C. elegans) UNC119 P A
203431_s_at Rho GTPase-activating protein RICS P A
203702_s_at tubulin tyrosine ligase-like family TTLL4 P A
203785_s_at DEAD (Asp-Glu-Ala_Asp) box DDX28 P A
203834_s_at trans-golgi network protein 2 TGOLN2 P A
203890_s_at death-associated protein kinase 3 DAPK3 P P
204149_s_at glutathione S-transferase M4 GSTM4 P A
204278_s_at estrogen receptor binding site associated EBAG9 P P
204292_x_at serine/threonine kinase 11 STK11 P A
204357_s_at LIM domain kinase 1 LIMK1 P A
208907_s_at mitochondrial ribosomal protein S18B MRPS18B P A
209202_s_at exotoses (multiple)-like 3 EXTL3 M A
210983_s_at MCM7 minichromosome maintanence MCM7 P A
211370_s_at mitogen-activated protein kinase kinase 5 MAP2K5 P A
211513_s_at opioid growth factor receptor OGFR P A
213772_s_at golgi associated, ARF binding protein 2 GGA2 P A
214610_at cytochrome P450, family 11, subfamily B CYP11B1 P M
216971_s_at plectin 1 PLEC1 P A
217770_at phosphatidylinositol glycan, class T PIGT P A
219646_at Hypothetical protein FLJ20186 FLJ20186 P A
219807_x_at RAB4B, member RAS oncogene family RAB4B P A
doi:10.1371/journal.pone.0006484.t002
Figure 6. A – Volcano-plot of the comparison between SCD and control samples. The X axis represents the fold change and the Y axis represents the
P value. B–Correlation of differentially expressed genes in PAX and PAX-GR samples.
doi:10.1371/journal.pone.0006484.g006
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PLoS ONE | www.plosone.org 8 August 2009 | Volume 4 | Issue 8 | e6484Figure 7. Heat Map of differential gene expression in PAX-GR in sickle cell disease (n=5) in comparison to control subjects (n=5).
Cluster analysis was applied to gene expression data derived from all probes on HG-U133 plus 2.0 at FDR 10% and FC .5.0. The level of expression of
each gene in each sample relative to the median level of expression of that gene across all samples is represented using a red, black and green color
scale (green – below median; black – equal to median; red - above median). The dendrogram displays the unsupervised clustering of patients and
control subjects using the differentially expressed gene list.
doi:10.1371/journal.pone.0006484.g007
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PLoS ONE | www.plosone.org 9 August 2009 | Volume 4 | Issue 8 | e6484importantly, the basis of sample segregation appears to be dependent
on sample types rather than the biological nature of the samples
suggesting that PAX and PAX –GR even after globin depletion have a
unique expression profile comp a r e dt oP B M C sa n dt h i sc o u l db e
attributed to the presence of cells other than mononuclear cells in the
whole blood RNA. The improvement in detection sensitivity after
globin depletion also permitted detection of several genes that were
masked by globins in the original PAX samples.
Previous studies on the effects of globin reduction from whole
blood suggestedthat globindepletioncanintroduce transformations
to original gene expression profile [13]. On the contrary, our
comparative analysis on the different sample types as shown by the
Venn diagram clearly demonstrated high fidelity in gene expression
with a high degree of overlap (88–94%) between the PAX and
PAX-GR samples. The globin depletion process appears to be
advantageousasitreducesthe variabilityofdatabetweensamplesas
shown by the scatter plot and the error analyses. More importantly,
depletion of globins led to unmasking of more than 3000 transcripts
in the whole blood samples which GO analysis indicates have
biological process functions such as transcription, intracellular
Table 3. List of differentially regulated genes in SCD from PAX-GR.
Probe set ID Gene Title Gene Symbol FC
202411_at interferon, alpha inducible protein 27 1F127 82.87
214407_x_at glycophorin B GYPB 22.75
216063_at hemoglobin, beta HBBP1 20.22
205950_s_at carbonic anhydrase I CA1 19.71
211821_x_at glycophorin A GYPA 17.65
203502_at 2,3-bisphosphoglycerate mutase BPGM 16.58
203115_at ferrochelatase (protoporphyria) FECH 12.26
217799_x_at ubiquitin-conjugating enzyme E2H UBE2H 9.66
209301_at carbonic anhydrase II CA2 8.66
206834_at hemoglobin, delta HBD 7.90
59644_at BMP2 inducible kinase BMP2K 7.02
216984_x_at Immunoglobulin lambda IGLC2 6.48
225123_at Sestrin 3 SESN3 6.15
212166_at exportin 7 XPO7 6.09
201629_s_at acid phosphatase 1 ACP1 5.50
202922_at glutamate-cysteine ligase GCLC 5.26
214433_s_at selenium binding protein 1 SELENBP1 5.04
201060_x_at stomatin STOM 4.88
207793_s_at erythrocyte membrane protein band 4.1 EPB4.1 4.70
202869_at 29,59-oligoadenylate synthetase 1 OAS1 4.63
212592_at Immunoglobulin J IGJ 3.43
211643_x_at Immunoglobulin kappa IGKC 3.22
210357_s_at spermine oxidase SMOX 3.19
205483_s_at interferon, alpha-inducible protein G1P2 3.16
39729_at peroxiredoxin 2 PRDX2 3.07
240336_at hemoglobin mu HBM 3.00
223084_s_at cyclin D-type binding-protein 1 CCNDBP1 2.86
204949_at intercellular adhesion molecule 3 ICAM3 0.49
211982_x_at exportin 6 XPO6 0.47
201041_s_at dual specificity phosphatase 1 DUSP1 0.47
204174_at arachidonate 5-lipoxygenase ALOX5AP 0.42
226333_at interleukin 6 receptor IL6R 0.40
207094_at interleukin 8 receptor, alpha IL8RA 0.39
220001_at peptidyl arginine deiminase, type IV PADI4 0.33
210484_s_at tumor necrosis factor receptor TNFRSF10C 0.33
201087_at paxillin PXN 0.32
207008_at interleukin 8 receptor, beta IL8RB 0.32
204655_at chemokine (C-C motif) ligand 5 CCL5 0.29
206515_at cytochrome P450, family 4 CYP4F3 0.24
doi:10.1371/journal.pone.0006484.t003
Whole Blood Gene Expression
PLoS ONE | www.plosone.org 10 August 2009 | Volume 4 | Issue 8 | e6484transport and biochemical signaling. This eventually led to an
improvement in the degree of overlap between PAX-GR and
PBMCs at 73–80%. The unmasking of genes by globin depletion
process also led an increase in the identification of transcripts that
are differentially regulated in sickle cell disease and these
differentially regulated genes include red cell specific transcripts
such as ankyrin, erythrocyte membrane protein band 3 and band 4,
hemoglobins and glycophorin A. Transcripts such as BMP2 kinase,
selenium binding protein, exportin, spermine oxidase, peroxire-
doxin 2, chemokines, interleukin receptor and peptidyl arginine
deaminasethat areknown tobe keyregulatorsinredoxmetabolism,
inflammatory process also demonstrated differential regulation in
sickle cell disease.Thislist ofgeneswithstatisticalfiltersat20%FDR
and FC .2 differed considerably to the list obtained from PBMCs
and this could be explained by the heterogeneous mixture of cells in
whole blood. We then compared 112 differentially regulated genes
(5% FDRand FC.1.2)fromourprevious study on PBMCsusing a
larger set of patients and controls to the current study by parametric
analysis. By doing so, it was evident that PBMCs from the current
study correlated to a large extent to the previous study with an R
value of 0.51 followed by PAX-GR (R=0.41) and PAX with an R
value of only 0.21. Though these correlation coefficient values are
notashigh asone would expectthemto be,ithas tobe remembered
here that the two studies were performed using a completely
different set of patients and volunteers using two different gene
chips. Nevertheless, correlation studies clearly showed that globin
reduction by unmasking several hundred genes in whole blood
generatesa gene expressionprofile thatismoderatelycomparableto
the expression profile of PBMCs.
This study thereby demonstrates that application of globin
reduction process to whole blood is highly advantageous to
generate meaningful data from microarrays. From a biological
perspective, the globin depleted PAX gene versus the PBMC
difference expression profile provided a window into real time
erythrocyte expression profiles in vascular diseases In clinical
investigations on hematological diseases such as sickle cell anemia,
thalassemia, G6PD, pyruvate kinase deficiency and in malaria
where the early red blood cell progenitors represent major
contributors to pathophysiology, insights into the transcription
profile of these cells may contribute greatly to our understanding
of mechanism of disease, prognosis, and responses to therapeutics.
The combination of globin mRNA reduction after whole-blood
RNA stabilization represents a robust clinical research methodol-
ogy for the discovery of biomarkers for hematologic diseases and in
multicenter clinical trials investigating a wide range of nonhema-
tologic disorders where fractionation of cell types is impracticable.
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